INTEGRATED BIOPHARMA INC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 225 LONG AVENUE, HILLSIDE, NJ, 07205
Mailing Address 225 LONG AVENUE, HILLSIDE, NJ, 07205
Phone 9739260816
Fiscal Year End 0630
EIN 222407475
Financial Overview
FY2025
$0.03
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 11, 2026 | View on SEC |
| 4 Insider stock transaction report | December 10, 2025 | View on SEC |
| 4 Insider stock transaction report | December 10, 2025 | View on SEC |
| 4 Insider stock transaction report | December 10, 2025 | View on SEC |
| 8-K Current report of material events | December 1, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 10, 2025 | View on SEC |
| 8-K Current report of material events | November 10, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | October 28, 2025 | View on SEC |
| 10-K Annual financial report | September 23, 2025 | View on SEC |
Annual Reports
10-K September 23, 2025
- Revenue grew 8% to $185 million with 15% profit increase to $12 million.
- Launched a successful 'stress relief' supplement line that sold out twice.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.